Evotec AG is a German-based drug discovery solutions company that operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, pain, oncology, inflammation and cardiovascular, metabolic and infectious diseases. Its sole mission is to build a partnered product pipeline based on high quality drug discovery and science and technology through efficient collaborations. Evotec has had significant drug discovery innovations in its 20-year history. It provides drug discovery expert services to pharmaceutical and biotechnology companies as well as to academic institutions. Evotec focuses on quality-driven services and innovative alliances. It has several significant long-term discovery alliances with well-established industry players such as Bayer, Boehringer Ingelheim, the CHDI Foundation, Genentech, Janssen Pharmaceuticals, AstraZeneca and Ono Pharmaceuticals.
Moreover, the company has many existing partnerships and product candidates available in both clinical and pre-clinical development. Under these partnerships, Evotec has collaborated with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes. Furthermore, these partnerships extend with Janssen Pharmaceuticals in the field of depression along with Roche to assist in the area of Alzheimer’s disease. According to Alpha Deal Group’s recent report, Evotec has generated 100 lead series, 30 pre-clinical candidates and 20 clinical compounds. It recently introduced a rich Phase 3-1 product pipeline, which includes first in class targets. The company has profitably been growing its business, driven by milestones and a strong cash position.
Evotec AG as a leading industrial application partner will be responsible for four key objectives: adaptation of hierarchical GPCR modelling protocol (HGMP) to HPC platform, developing of the new HGMP-HPC based tools / plugins that require high scale calculations, testing and application of HGMP-HPC integrated technology in real drug discovery cases within the CoE and to make it available to third parties seeking assistance from the CoE and/or from Evotec, and dissemination of the results of this work to our partners in academia and in pharma & biotech companies in order to stimulate follow-on research. Evotec will also to publish the outcome of this work in peer-reviewed journals and at scientific conferences.